Annexon Appoints Industry Veteran, Dr. Rick Artis, as Chief Scientific Officer to Support the Advancement and Expansion of Complement-focused Portfolio

January 6, 2023

https://www.globenewswire.com/news-release/2023/01/06/2584298/0/en/Annexon-Appoints-Industry-Veteran-Dr-Rick-Artis-as-Chief-Scientific-Officer-to-Support-the-Advancement-and-Expansion-of-Complement-focused-Portfolio.html

BRISBANE, Calif., Jan. 06, 2023 (GLOBE NEWSWIRE) — Annexon, Inc. (Nasdaq:ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, today announced that Dean “Rick” Artis, Ph.D., has been appointed as chief scientific officer (CSO), succeeding Larry C. Mattheakis, Ph.D. Dr. Artis most recently served as CSO at Octant Bio and earlier, led efforts at Annexon for the discovery of the company’s small molecule classical complement inhibitors, including ANX1502.

Read more at globenewswire.com

Related news for (ANNX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.